百克生物2026年研发计划曝光，重点推进鼻喷流感疫苗与mRNA疫苗

Group 1 - The company plans to advance the Phase III clinical trial of its liquid nasal spray influenza vaccine for the age group of 18-59 in 2026 [1] - The company aims to accelerate the development of its HSV-2 mRNA vaccine to strengthen its mRNA technology platform [1]